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Curcumin, the phytochemical component in turmeric, is used as a dietary spice and a topical ointment for the treatment of
inﬂammation in India for centuries. Curcumin (diferuloylmethane) is relatively insoluble in water, but dissolves in acetone,
dimethylsulphoxide, and ethanol. Commercial grade curcumin contains 10–20% curcuminoids, desmethoxycurcumin, and bis-
desmethoxycurcumin and they are as eﬀective as pure curcumin. Based on a number of clinical studies in carcinogenesis, a daily
oral dose of 3.6g curcumin has been eﬃcacious for colorectal cancer and advocates its advancement into Phase II clinical studies.
In addition to the anticancer eﬀects, curcumin has been eﬀective against a variety of disease conditions in both in vitro and in vivo
preclinical studies. The present review highlights the importance of curcumin as an anti-inﬂammatory agent and suggests that the
beneﬁcial eﬀect of curcumin is mediated by the upregulation of peroxisome proliferator-activated receptor-γ (PPAR-γ) activation.
Copyright © 2007 Asha Jacob et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Turmeric, Curcuma longa Linn., plant is a perennial herb
belonging to the ginger family, Zingiberaceae, and is gener-
ally cultivated in south and southeast tropical Asia. The rhi-
zome, which is also referred to as the root of this plant, is the
most useful part and is used as a dietary spice for centuries.
It has been used both orally and as a topical ointment to
treat a variety of disorders. It is widely used in traditional In-
dian Ayurvedic medicine to treat hepatic disorders, anorexia,
cough, diabetic wounds, rheumatoid arthritis, and sinusitis.
Turmeric paste in slaked lime is a popular home remedy for
the treatment of inﬂammation and wounds. Ancient texts of
Indian medicine describe the use of curcumin in inﬂamma-
tory diseases, wound healing, and abdominal problems [1].
2. CHEMICAL PROPERTIES
Curcumin, the most active component of turmeric, makes
up 2–5% of this spice. The yellow color of the turmeric
is due to the curcumin compound. Curcumin (C21H20O6)
was ﬁrst described in 1910 by Lampe and Milobedeska
and shown to be a diferuloylmethane, 1,7-bis (4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione [2], and is prac-
tically insoluble in water. Curcumin is a bis-α-β-unsaturated
β-diketone; under acidic and neutral conditions, the bis-keto
form of the compound predominates, and at pH above 8, the
enolate form is generally found [3] .H e n c ea tp H3 – 7 ,i ta c t s
as an extraordinarily potent H-atom donor and above pH 8,
it acts mainly as an electron donor, a mechanism more suit-
able to the scavenging or antioxidant properties of curcumin
[4]. Curcumin is quite unstable at basic pH and degrades
within 30 minutes. Human blood or antioxidants such as
ascorbic acid, or the presence of 10% fetal bovine serum in
the culture media prevents this degradation [5]. Curcumin
has a molecular weight of 368.7 and the commercial grade
curcumin contains curcuminoids, 10–20% desmethoxycur-
cumin and less than 5% bisdesmethoxycurcumin [3]. The
commercial grade curcumin is just as eﬀective as pure cur-
cumin in preclinical models of carcinogenesis [6].
3. PHARMACOKINETIC AND PHARMACODYNAMIC
PROPERTIES
Absorption, metabolism and tissue distribution are impor-
tant parameters to render a compound to be used as a thera-
peuticagent.Inthisregard,inanearlystudywherecurcumin2 PPAR Research
was administered to rats at a dose of 1g/kg body weight in
diet, 75% of the dose was excreted in the feces and trace
amounts were present in urine [7]. A few years later, it was
determined that 60% of orally administered curcumin was
absorbed but most of it has been changed to glucuronide
and sulphate conjugates and excreted in the urine [8]. In-
travenous or intraperitoneal administration of curcumin in
rodents resulted in the presence of large quantities of cur-
cumin and its metabolites in the bile. This suggests that
curcumin undergoes transformation during absorption via
the intestine and possibly recirculates [9, 10]. Another study
showed that coadministration of curcumin with piperine, a
compound found in pepper vine and peppers, increased the
bioavailabilityofcurcuminfollowingoraldosingpresumably
dueto theinhibition ofxenobiotic glucuronidation bypiper-
ine [11]. Thus, curcumin exhibits low systemic bioavailabil-
ity after oral dosing in rodents and may undergo intestinal
metabolism.
Only a limited number of studies have been shown for
the pharmacokinetic properties of curcumin in humans and
majority of these studies were conducted in cancer patients.
In this regard, Cheng et al. administered 0.5 to 8g daily of
curcumin orally for 3 months to patients with high-risk pre-
malignant conditions of the bladder, skin, cervix, stomach,
ororalmucosa.Serumconcentrationsofcurcuminpeakedat
1-2 hour(s) posttreatment with a gradual decline within 12
hours.The8g/dayresultedinabout1.75μMcurcumininthe
serum [12]. In a pilot study using a standardized oral Cur-
cuma extract, doses up to 180mg of curcumin per day were
administered to patients with advanced colorectal cancer for
upto4monthswithoutmuchtoxicity[13].InanotherPhase
I study of 15 patients with advanced colorectal cancer, six pa-
tients were given 3.6g of curcumin daily for up to 4 months.
This daily dosing resulted in the detectable level of curcumin
and its conjugates in plasma. Urine samples from these pa-
tients showed 0.1 to 1.3μMc u r c u m i na n dt r a c el e v e l so fi t s
conjugates.Sincecurcumincanbedetectedintheurinesam-
ples, urine analysis could be used as the measure of general
compliance and the assessment of inter- and intraindividual
variability [14].
Along with the dose studies, malignant colorectal tissues
were analyzed in patients consuming 3.6g of curcumin daily
for 7 days prior to surgery. The concentrations of curcumin
in normal and malignant colorectal tissues of patients were
12.7±5.7a n d7 .7±1.8nmol/g tissue, respectively. Curcumin
conjugates were seen in the intestinal tissue of these patients
and trace levels of curcumin were found in peripheral cir-
culation [14]. Thus, a daily oral dose of 3.6g of curcumin
resulted in a pharmacologically eﬃcacious level in colorec-
tal tissues. Further studies are warranted for the eﬃcacy of
this compound in other diseases as well as diﬀerent types of
cancer.
4. BENEFICIAL EFFECTS
After a long-term use in traditional Ayruvedic medicine,
modern scientiﬁc community discovered that curcumin has
beneﬁcial eﬀects on a variety of diseases and pathological
conditions [15]. Curcumin has shown to possess anticancer
eﬀects by blocking transformation, tumor initiation, tumor
promotion, invasion, angiogenesis, and metastasis [2]. It has
been demonstrated to have a dose-dependent chemopreven-
tive eﬀect in animal systems of colon, duodenal, stomach,
esophageal, and oral carcinogenesis [16]. Low incidence of
colon cancer among Indians has been attributed to the use of
turmeric in Indian cooking [17]. In addition to its anticancer
eﬀects, curcumin has been eﬀective against a variety of con-
ditions in in vitro and in vivo preclinical studies [15]. Cur-
cumin has shown to be eﬀective against atherosclerosis and
myocardial infarction. The administration of curcumin re-
duced blood sugar and glycosylated hemoglobin levels in an
alloxan-induced rat model of type 2 diabetes. Curcumin ap-
pears to suppress oxidative damage, inﬂammation, cognitive
deﬁcits,andamyloid accumulationinAlzheimer’s disease. In
addition, curcumin appears to show protective eﬀects in cys-
ticﬁbrosis,humanimmunodeﬁciencyvirus,andexperimen-
tal alcoholic liver disease.
Treatment with curcumin in an animal model of wound
healing produced large inﬁltration of macrophages, neu-
trophils, and ﬁbroblast compared to untreated wounds. The
treatment resulted in enhanced expression of ﬁbronectin
and collagen by ﬁbroblasts and increased the rate of for-
mation of granulation tissue suggesting an enhancement in
wound healing [18]. Curcumin is shown to modulate an-
giogenesis and uncontrolled angiogenesis had been associ-
ated with pathological conditions such as tumor growth and
metastasis, rheumatoid arthritis, diabetic retinopathy, and
hemangiomas [19, 20]. Curcumin treatment results in in-
hibition of angiogenic diﬀerentiation of human umbilical
vein endothelial cells (HUVEC) [21], and inhibits basic ﬁ-
broblast growth factor-induced corneal neovascularization
in the mouse cornea [22], indicating its antiangiogenic ef-
fect. Curcumin is also a strong antioxidant compared to vi-
tamins C and E [23]. Oxidative stress plays a major role in
the pathogenesis of various diseases including myocardial is-
chemia, cerebral ischemia-reperfusion injury, hemorrhage,
shock, hypoxia, and cancer. In a hemorrhage/resuscitation
injury model, pretreatment with curcumin resulted in a sig-
niﬁcant decrease in liver enzyme, aspartate transaminase,
and the liver cytokines, IL-1α,I L - 1 β, IL-2, IL-6, and IL-10
[24].
Perhaps the most important eﬀect of curcumin is its
anti-inﬂammatory properties and this is the major focus of
this review. Only a few clinical studies have been reported
on the eﬀect of administration of curcumin on inﬂamma-
tory diseases [25–28]. However, curcumin has been known
to possess anti-inﬂammatory activity in experimental ani-
mals [29]. In this regard, we have recently shown that cur-
cumin has beneﬁcial eﬀects in sepsis [30]. Male Sprague
Dawley rats were treated with a bolus intravenous injection
of 0.2μmol of curcumin followed by a continuous infusion
of 0.24μmol/day for 3 days via a 2-mL alzet pump. Then
the rats were subjected to sepsis by cecal ligation and punc-
ture (CLP), a widely used animal model of sepsis. Twenty
hours following CLP (i.e., the late stage of sepsis), the rats
were killed and the blood and tissue samples were collected.
The blood samples were analyzed for tissue injury param-
eters, alanine aminotransferase, aspartate aminotransferase,Asha Jacob et al. 3
lactate, and TNF-α. As expected, sepsis induced a two-to-
three-fold increase in the circulating levels of these injury
markers compared to sham controls. Pretreatment with cur-
cuminsigniﬁcantlyreducedtheselevelstothatofsham.Sim-
ilar results were observed when curcumin was administered
5 hours after the onset of sepsis. In an additional group of
animals, a 10-day survival study was conducted after CLP in
animals pretreated with curcumin for 3 days. Sepsis caused
a 56–69% mortality rate while pretreatment with curcumin
improved the survival rate to 100% throughout the 10-day
observation period. Thus, we have demonstrated the anti-
inﬂammatory eﬀe c to fc u r c u m i ni na ni nv i v oe x p e r i m e n -
tal model of sepsis. We have also shown that pretreatment
with 50μM curcumin in a macrophage cell line, RAW 264.7
cells, produced 23% and 71% reduction in LPS-induced in-
creases in TNF-α gene expression and protein levels, respec-
tively [30]. At 100μM curcumin, a reduction by 60% and
99% in the LPS-stimulated increases in TNF-α gene expres-
sion and protein levels were observed, respectively. These
data prompted us to explore the potential mechanisms as-
sociated with curcumin-induced anti-inﬂammatory eﬀects.
5. POTENTIAL MECHANISMS
The mechanism by which curcumin induces its anti-
inﬂammatory eﬀects is yet to be elucidated. Studies
have shown that peroxisome proliferator-activated recep-
tor gamma (PPAR-γ) has been associated with anti-
inﬂammatoryeﬀects.PPARsbelongtothesuperfamilyofnu-
clear receptors consisting of three genes that give rise to three
diﬀerent subtypes, PPAR-α,P P A R - δ, and PPAR-γ.A m o n g
them, PPAR-γ is the most widely studied form. Upon lig-
and binding, PPAR-γ forms heterodimers with the retinoid
X receptor and binds to a peroxisome proliferation response
element (PPRE) in a gene promoter leading to regulation
of gene transcription [31]. In that regard, we have recently
shown that gene and protein levels of PPAR-γ in the liver
decreased by approximately 50% at 20 hours after the on-
set of sepsis. Pretreatment with curcumin for 3 days at 0.24
μmol/kg body weight in these septic rats produced 45% and
65% increase in PPAR-γ mRNA and protein levels, respec-
tively. The mRNA and protein levels of PPAR-γ in the treat-
ment group were similar to sham controls [30]. To con-
ﬁrm that the beneﬁcial eﬀect of curcumin in sepsis is me-
diated through PPAR-γ pathway, a separate group of animals
w e r et r e a t e df o r3d a y sw i t hP P A R - γ antagonist, GW9662, at
1.5mg/kg along withcurcumin at0.24μmol/kg body weight.
Then, rats were subjected to sepsis by CLP and 20 hours af-
ter surgery,blood and tissue samples were collected.Concur-
rent administration of curcumin and GW9662 in the septic
rats completely abolished the eﬀects of curcumin on serum
levels of the liver enzymes, ALT and AST, lactate, and TNF-
α [30]. Furthermore, in vitro using RAW 264.7 cells, pre-
treatment with 50 and 100μM curcumin increased PPAR-
γ mRNA levels by 86% and 125%, respectively, compared
to LPS treatment alone. Consistent with this, immunohisto-
chemical staining of RAW 264.7 cells with PPAR-γ antibody
showed increased nuclear PPAR-γ staining in cells pretreated
with100μMcur cuminc ompar edt oLPSalone.Thissuggests
that the beneﬁcial eﬀect of curcumin appears to be mediated
by the upregulation of PPAR-γ [30].
Both in vivo and in vitro studies have shown that
activation of PPAR-γ by thiazolidinediones (TZDs), the
class of insulin-sensitizing drugs, or 15d-PG-J2 has anti-
inﬂammatory eﬀects [32–34]. TZDs are the synthetic ag-
onists of PPAR-γ and PGJ2 series have been identiﬁed as
the natural ligand of PPAR-γ. In that regard, Zingarelli et
al. showed that PPAR-γ expression was markedly reduced
in lung and thoracic aorta after CLP sepsis. Furthermore,
in vivo treatment with 15d-PGJ2 or ciglitazone, one of the
TZDs, following CLP ameliorated hypotension and survival,
blunted cytokine production and reduced neutrophil inﬁl-
tration in lung, colon, and liver. These beneﬁcial eﬀects of
PPAR-γ ligands were associated with the reduction of IκB ki-
nase complex, JNK activation, and reduction of NF-κBa n d
AP-1 pathways [32]. Recent evidence suggests that PPAR-
γ ligands exert their eﬀects in HT-29 colon cancer cells by
phosphorylation of the PPAR-γ by the extracellular signal-
regulated kinase 1/2, thereby causing a physical interaction
with the p65 subunit of the NF-κB preventing the activation
of the NF-κBp a t h w a y[ 35]. The inhibition of cell signaling
pathways, Akt, NF-κB, AP-1, or JNK, has been implicated as
the mechanism responsible for apoptosis induction by cur-
c u m i n .Ar e c e n ts t u d yr e p o r t e dt h a tc u r c u m i np o t e n t i a t e s
the antitumor eﬀect of gemcitabine in pancreatic cancer by
suppressing proliferation, angiogenesis, and downregulating
NF-κBa n dN F - κB-regulated gene products [36]. However, it
is plausible that curcumin induced anti-inﬂammatory eﬀect
caused by the upregulation of PPAR-γ is associated with the
NF-κB pathway. Future studies are warranted for such con-
clusion.
Numerous studies have shown the importance of cur-
cumin as a potent immunomodulatory agent in T cells, B
cells, neutrophils, natural killer cells, dendritic cells, and
macrophages [37]. In that regard, we have shown that cur-
cumin induces apoptosis in human neutrophils [38]. Neu-
trophils are the ﬁrst line of host immune defense against
foreign substances and their biological activities are tightly
regulated by apoptosis. Delayed neutrophil apoptosis has
been associated with acute lung injury and sepsis [39–41].
We ﬁrst examined the eﬀe c to fc u r c u m i no nb o t hs p o n t a -
neous neutrophil apoptosis and apoptosis of neutrophils fol-
lowing transmigration across a human lung endothelium-
epithelium bilayer. The results showed that curcumin in-
creased constitutive neutrophil apoptosis and abrogated the
transbilayer migration-induced delay in neutrophil apop-
tosis. To determine the impact of curcumin on neutrophil
function,weperformedmyeloperoxidaseactivityandmigra-
tion assays. Curcumin treatment decreased neutrophil mi-
gration and myeloperoxidase release indicating a reduction
in neutrophil activation. To elucidate the potential mech-
anism, we have examined the eﬀe c to fc u r c u m i no np 3 8
mitogen-activated protein kinase and caspase-3 activity. A
marked increase in p38 phosphorylation and caspase-3 ac-
tivity was observed in the presence of curcumin. Treat-
ment of p38-speciﬁc inhibitor, SB203580, suppressed both
curcumin-induced apoptosis and caspase-3 activation. From4 PPAR Research
this study, we concluded that curcumin induces apoptosis in
human neutrophil and its eﬀect is mediated by the activation
of p38 and caspase-3 activity.
6. FUTURE STUDIES AND PERSPECTIVES
In this review, we highlighted the importance of curcumin
as an anti-inﬂammatory compound. We also demonstrated
that the beneﬁcial eﬀect of curcumin in sepsis appears to
be mediated by the upregulation of PPAR-γ, leading to the
suppressionofproinﬂammatorycytokine,TNF-αexpression
and release. Studies on the eﬀect of both synthetic and nat-
ural ligands of PPAR-γ on polymicrobial sepsis are also re-
viewed. Curcumin eﬀect on apoptosis and potential mecha-
nisms is also discussed.
In the future, we will explore the mechanism by which
curcumin-induced upregulation of PPAR-γ leads to the sup-
pression of TNF-α release to provide protection in sepsis.
Themajorquestionweneedtoaddressiswhethercurcumin-
induced anti-inﬂammatory eﬀects are direct or indirect. One
possible scenario is that curcumin as a ligand binds to the
PPAR-γ receptor and heterodimerizes with the retinoic acid
receptor and directly binds to the PPRE of TNF-α gene itself
or genes which codes for its upstream mediators and inacti-
vatesthem.Secondly,curcuminbindstoitsownreceptorand
the ligand-receptor interaction activates signaling pathways
leading to the upregulation of PPAR-γ and the subsequent
suppression of inﬂammatory cytokine release. In vitro stud-
ieswithmacrophagesarerecommendedtodissecttheprecise
mechanism of curcumin-induced anti-inﬂammatory eﬀects.
Another question we need to address is whether curcumin
itself or its metabolites is the active compound responsi-
ble for anti-inﬂammatory eﬀects. Prior studies on the anti-
inﬂammatory nature of curcumin were done on curcumin
itself. Further studies with curcumin metabolites, curcumin
sulfate, and curcumin glucuronide will warrant answering
such questions. Several studies suggest that PPAR-γ ligand,
15d-PGJ2, protects organs from tissue injury caused by is-
chemia/reperfusion injury, hemorrhage/resuscitation, or en-
dotoxemia [42–44]. The eﬀe c to fc u r c u m i no no t h e rm o d e l s
of tissue injury should also be explored. Thus, more in vitro
and preclinical researches are needed to render curcumin or
its metabolites as therapy for sepsis and/or other models of
tissue injury.
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